Jensen, Jens-Ulrik <br/><br/>
The Procalcitonin And Survival Study (PASS) - a randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker Procalcitonin and pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients.  [electronic resource] 

 -  BMC infectious diseases  Jul 2008 
 - 91 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1471-2334 
<br/><br/><label>Standard No.: </label>10.1186/1471-2334-8-91  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Biomarkers--blood<br/>Calcitonin--blood<br/>Calcitonin Gene-Related Peptide<br/>Critical Illness--mortality<br/>Female<br/>Humans<br/>Intensive Care Units<br/>Male<br/>Protein Precursors--blood<br/>Sepsis--diagnosis